Terms: = Germ cell tumor AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
2221 results:
1. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract] [Full Text] [Related]
2. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract] [Full Text] [Related]
3. Recurrence Patterns and Surveillance Imaging in Pediatric Brain tumor Survivors.
Cacciotti C; Lenzen A; Self C; Pillay-Smiley N
J Pediatr Hematol Oncol; 2024 Apr; 46(3):e227-e232. PubMed ID: 38447113
[TBL] [Abstract] [Full Text] [Related]
4. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
Yadav S; Lawhn-Heath C; Paciorek A; Lindsay S; Mirro R; Bergsland EK; Hope TA
J Nucl Med; 2024 Mar; 65(3):409-415. PubMed ID: 38428966
[TBL] [Abstract] [Full Text] [Related]
5. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
Mensah JA; Fei-Zhang DJ; Rossen JL; Rahmani B; Bentrem DJ; Stein JD; French DD
Ann Surg Oncol; 2024 May; 31(5):3302-3313. PubMed ID: 38418655
[TBL] [Abstract] [Full Text] [Related]
7. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract] [Full Text] [Related]
8. tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF; Schreibelt G; Bloemendal M; van Willigen WW; Hins-de Bree S; de Goede AL; de Boer AJ; Bos KJH; Duiveman-de Boer T; Olde Nordkamp MAM; van Oorschot TGM; Popelier CJ; Pots JM; Scharenborg NM; van de Rakt MWMM; de Ruiter V; van Meeteren WS; van Rossum MM; Croockewit SJ; Koeneman BJ; Creemers JHA; Wortel IMN; Angerer C; Brüning M; Petry K; Dzionek A; van der Veldt AA; van Grünhagen DJ; Werner JEM; Bonenkamp JJ; Haanen JBAG; Boers-Sonderen MJ; Koornstra RHT; Boomsma MF; Aarntzen EHJ; Gotthardt M; Nagarajah J; de Witte TJM; Figdor CG; de Wilt JHW; Textor J; de Groot JWB; Gerritsen WR; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1632. PubMed ID: 38395969
[TBL] [Abstract] [Full Text] [Related]
10. Hydrophilic molecularly imprinted resin-hexagonal boron nitride composite as a new adsorbent for selective extraction and determination of a carcinoid tumor biomarker in urine.
Cao J; Wang M; Han Y; Wang M; Yan H
Anal Chim Acta; 2024 Mar; 1294():342289. PubMed ID: 38336412
[TBL] [Abstract] [Full Text] [Related]
11. Porcine-human glioma xenograft model. Immunosuppression and model reproducibility.
Hoopes PJ; Tavakkoli AD; Moodie KA; Maurer KJ; Meehan KR; Wallin DJ; Aulwes E; Duval KEA; Chen KL; -Burney MAC; Li C; Fan X; Evans LT; Paulsen KD
Cancer Treat Res Commun; 2024; 38():100789. PubMed ID: 38262125
[TBL] [Abstract] [Full Text] [Related]
12. The neuroprotective effect of LCZ696 on methamphetamine-induced cognitive impairment in mice.
Qian L; Ruan Y; Gong X; Yu Z; Lin S; Li X; Shen Y; Luo H; Si Z; Liu Y
Neurosci Lett; 2024 Feb; 823():137630. PubMed ID: 38215873
[TBL] [Abstract] [Full Text] [Related]
13. [Analysis of the influencing factors of short-term and long-term facial nerve function after vestibular schwannoma resection via suboccipital retrosigmoid approach].
Ren JW; Xu J; Huang X; Xu M; Chen MY; Wang Y; Wang W; Zhong P
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Dec; 58(12):1183-1190. PubMed ID: 38186092
[No Abstract] [Full Text] [Related]
14. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
15. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
16. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in germany: the non-interventional study coveNIS.
Kähler KC; Debus D; Schley G; Göppner D; Hassel JC; Meier F; Terheyden P; Stadler R; Tüting T; Kaatz M; Hoff NP; Masoudi E; Zdanowicz-Specht A; Nguyen MT; Mohr P
Melanoma Res; 2024 Feb; 34(1):44-53. PubMed ID: 37962220
[TBL] [Abstract] [Full Text] [Related]
17. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract] [Full Text] [Related]
18. [Rheumatic adverse events due to immune checkpoint inhibitors].
van Binsbergen WH; Heslinga SC; Lems WF; Tsang-A-Sjoe MWP; Labots M; van der Laken J
Ned Tijdschr Geneeskd; 2023 Nov; 167():. PubMed ID: 37930161
[TBL] [Abstract] [Full Text] [Related]
19. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract] [Full Text] [Related]
20. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract] [Full Text] [Related]
[Next]
